Resistant and Mutational Cells
Zev Wainberg, MD; Stanton L. Gerson, MD; and Sy Schlager, MD
Video Categories: Cancer Stem Cells and PMO Interview with the Innovator Series: Volume 11
Dr Wainberg and Dr Gerson talk about the efficacy limitations of cytotoxic chemotherapy on some cells for a variety of reasons.
PMO is pleased to offer the department “The Biomarker” to discuss the identification of biomarkers in patients with cancer and the prognostic/predictive impact and clinical decision-making implications of that marker. This month, we focus on KIT mutations in melanoma patients. Dr Sanjiv Agarwala provides his insights on this provocative topic.
Linda Bosserman provides insight into positive data around payer-provider collaborations